Pay with

USD

Supports Visa, Mastercard, SEPA & more

Flexible trading, zero fees

Use your crypto for payments worldwide

Basic

Trade crypto freely

Smart access to new on-chain tokens

Magnify your profit with leverage

Convert & Auto-Invest

Trade any size with no fees and no slippage

Get exposure to leveraged positions simply

Pre-Market Trading

Trade new tokens before listing

Advanced

Trade on-chain with Gate Wallet

Smart strategies with automated trading

Follow expert trading strategies

CrossEx Trading

One margin balance, shared across platforms

OTC Bank Transfer

Deposit and withdraw fiat

OTC trades with simple RFQ

Access hundreds of perpetual contracts

One platform for global traditional assets

Event Contracts

Predict price moves and seize opportunities

Trade European-style vanilla options

Unified Account

Maximize your capital efficiency

Introduction to Futures Trading

Learn the basics of futures trading

Join events to earn rewards

Use virtual funds to practice risk-free trading

Stock CFD Derivatives

Access real US stocks and ETFs

Trade quality Hong Kong-listed stocks

Real Korean stocks and top assets

Top Japanese stocks, all in one place

High leverage, 24/7 trading

Stocks Activities

Trade Popular Stocks and Unlock Generous Airdrops

Tokenized Stocks

Backed by real stock assets

Unlock full access to global stock IPOs

Launch

Collect candies to earn airdrops

Quick staking, earn potential new tokens

Hold GT and get massive airdrops for free

Unlock full access to global stock IPOs

Trade on-chain assets and earn airdrops

Earn futures points and claim airdrop rewards

Investment

Trade & earn at the same time

Earn interest with idle tokens

Stake cryptos to earn in PoS products

Auto-invest on a regular basis

Dual Investment

Profit from market volatility

Earn rewards with flexible staking

Limited-time 4% APR on USDT

Top-tier quant strategies

Earn reliable returns from Treasury RWAs

No lock-up, withdraw anytime

Pledge one crypto to borrow another

One-stop lending hub

Post, share, and explore crypto trends

Live crypto market analysis

Chat with crypto traders

What is happening in crypto

Crypto guides and educational resources

Crypto insights and industry updates

In-depth research and market analysis

More

Promotions

Activity Center

Participate in activities to earn rewards

Invite friends to earn referral rewards

Affiliate Program

Earn exclusive commission rewards

Grow influence and earn airdrops

Real-time platform updates

Huge fee discounts

Asset Management

One‑stop asset management solution

Enterprise digital asset solutions

Developers (API)

Connects to the Gate application ecosystem

Generous API rebate mechanisms

Trade on TradingView

Elevate your trading experience

AI

Your all-in-one conversational AI partner

Use Gate AI directly in your social App

Gate Blue Lobster, ready to go

Gate for AI Agent

AI infrastructure, Gate MCP, Skills, and CLI

Gate Skills Hub

From office tasks to trading, the all-in-one skill hub makes AI even more useful.

Others

Find FAQs and help guides

Grow with the champions

Proof of Reserves

Gate promises 100% proof of reserves

Keep your assets secure

Regulatory Licenses, Registrations, and Approvals

Sionna Therapeutics Stock Plunges 92% on Monday as SION-719 Cystic Fibrosis Drug Fails Mid-Stage Trial

2026-08-10 17:26:05

According to Sionna Therapeutics, SION stock plunged roughly 92% on Monday after the biotech firm's experimental cystic fibrosis drug SION-719 failed to meet its mid-stage trial goals. The drug, tested as an add-on therapy to Vertex's Trikafta in 15 cystic fibrosis patients, barely lowered sweat chloride levels—a key marker of protein function improvement—showing only a minor difference versus placebo that was not statistically significant. The company abandoned plans to advance SION-719 in this combination role and said it will preserve capital while assessing its path forward, ending the second quarter with approximately $268 million in cash. Vertex's stock rose 7% following the news. Stifel downgraded Sionna to Hold from Buy, lowering its price target to $7 from $55.

Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.

Related News

Tenax Therapeutics Stock Crashes 89% Today as TNX-103 Fails Phase 3 Trial

EPIC Plunges 52.83% in 24 Hours as BMT Surges 51.45% on Binance Spot Market

SK Hynix Surges Then Falls to Up 0.84% Overnight, Southern China 2x Bull ETF Drops Over 7% at Open

BICO Plummets 41% in 24 Hours as Market Sees Broader Volatility; TKO Surges 5.97%

SK Hynix Stock Plunges 52% in One Month; Pledges Q3 Shareholder Return Plan

In-Depth Analysis

Tenax Therapeutics Stocks Crash 89% After TNX-103 Phase 3 Trial Failure

Lucas Bennett08-10 14:27

AbCellera Awaits Phase 2 Data for ABCL635 Menopause Treatment

Lucas Bennett08-10 12:14

Single-Stock Leveraged ETFs Hit Worst Performance as 14 of 15 Bottom Funds

Lucas Bennett08-10 10:39

Comment

0/400

No comments